2017 Press Releases

Keyword Search
 
June 5, 2017
Lion Biotechnologies Announces Updated Data at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting from Ongoing LN-144 Phase 2 Clinical Trial
Data show clinically-meaningful outcomes in advanced metastatic melanoma patients who were all refractory to anti-PD-1 and most to anti-CTLA-4 with a median of three prior therapies SAN CARLOS, CA -- (Marketwired) -- 06/05/17 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced a poster presentation of additional data from 16 patients enrolled in the first cohort o... More »
June 1, 2017
Lion Biotechnologies Announces First Patient Dosed in Phase 2 Trial of LN-145 for Head and Neck Cancer
SAN CARLOS, CA -- (Marketwired) -- 06/01/17 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the first patient was dosed in its Phase 2 trial of LN-145 for the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. "We are pleased to have dosed our first patient in this trial evaluating LN-145 for the treatment ... More »
May 30, 2017
Lion Biotechnologies to Present at Jefferies 2017 Healthcare Conference
SAN CARLOS, CA -- (Marketwired) -- 05/30/17 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that President and Chief Executive Officer, Dr. Maria Fardis will present an overview of Lion's recent progress and 2017 plans at the upcoming Jefferies 2017 Healthcare Conference on Tuesday, June 6, 2017 at 8:30 a.m. E.T. in New York, NY. A live webcast of the present... More »
May 25, 2017
Lion Biotechnologies Announces Departure of Chief Financial Officer
SAN CARLOS, CA -- (Marketwired) -- 05/25/17 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that Gregory Schiffman, Chief Financial Officer, has decided to leave the company for personal reasons, preventing him from commuting from his residence in Portland, OR to the Company's corporate headquarters in San Carlos, CA. Mr. Schiffman will remain in his current rol... More »
May 19, 2017
Lion Biotechnologies Announces First Patient Dosed in Second Cohort of LN-144 Phase 2 Trial for Metastatic Melanoma
SAN CARLOS, CA -- (Marketwired) -- 05/19/17 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the first patient was dosed in the second cohort of its ongoing Phase 2 trial of LN-144 for the treatment of patients with metastatic melanoma. This cohort utilizes the company's generation 2 manufacturing process which includes cryopreservation of the outbound produ... More »
May 17, 2017
Lion Biotechnologies to Present New Data from Ongoing LN-144 Phase 2 Clinical Trial at 2017 American Society of Clinical Oncology Annual Meeting
SAN CARLOS, CA -- (Marketwired) -- 05/17/17 -- Poster to highlight new interim data from cohort one of ongoing Phase 2 trial of LN-144 in patients with metastatic melanoma First data readout for Lion-sponsored clinical trial investigating TIL Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology... More »
May 1, 2017
Lion Biotechnologies Reports First Quarter 2017 Financial Results
Company to Host Conference Call at 5:00pm ET Today SAN CARLOS, CA -- (Marketwired) -- 05/01/17 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today reported its first quarter 2017 financial results and provided a corporate update. "We started 2017 with a clear focus on execution toward expanding our manufacturing capacity, our clinical program and initiatio... More »
April 26, 2017
Lion Biotechnologies Announces New Manufacturing Services Agreement with PharmaCell
COLLABORATION WILL ESTABLISH OVERSEAS CAPACITY FOR MAKING TIL PRODUCTSAN CARLOS, CA -- (Marketwired) -- 04/26/17 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology (TIL), today announced that it has entered into a new three-year Manufacturing Services Agreement and related statements of work with PharmaCell B.V. (PharmaCell), a contract manufacturing services company based in the Net... More »
April 24, 2017
Lion Biotechnologies to Host Conference Call to Discuss First Quarter 2017 Financial and Operating Results on Monday, May 1, 2017
SAN CARLOS, CA -- (Marketwired) -- 04/24/17 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its first quarter 2017 financial and operating results after the close of the U.S. financial markets on Monday, May 1, 2017. Management will host a conference call and live audio webcast to discuss these results and provide a business updat... More »
April 19, 2017
Lion Biotechnologies Announces Strategic Alliance with MD Anderson Cancer Center to Conduct Clinical Trials of TILs in Multiple Solid Tumors
SAN CARLOS, CA and HOUSTON, TX -- (Marketwired) -- 04/19/17 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology and The University of Texas MD Anderson Cancer Center, today announced a multi-year strategic alliance agreement involving multi-arm clinical trials to evaluate the safety and efficacy of TIL therapy in ovarian cancer, various sarcomas, and pancreatic cancer. In ad... More »
April 18, 2017
Lion Biotechnologies Highlights Publication of New Translational Data in Science for TIL Therapy for Treatment of Cervical Cancer
SAN CARLOS, CA -- (Marketwired) -- 04/18/17 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, highlighted today that a publication in the journal Science provided new translational data from a clinical trial of TIL therapy for the treatment of advanced metastatic cervical cancer conducted at the Surgery Branch of the National Cancer Institute (NCI). This trial has be... More »
March 7, 2017
Lion Biotechnologies Reports Fourth Quarter and Full-Year 2016 Financial Results and Provides Corporate Update
Company to Host Conference Call at 4:30pm ET Today SAN CARLOS, CA -- (Marketwired) -- 03/07/17 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today reported its fourth quarter and full-year 2016 financial results and provided a corporate update. "During the second half of 2016, we significantly expanded our employee base, optimized the process of manufactu... More »
February 28, 2017
Lion Biotechnologies to Host Conference Call to Discuss Fourth Quarter and Full Year 2016 Financial and Operating Results on Tuesday, March 7, 2017
SAN CARLOS, CA -- (Marketwired) -- 02/28/17 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its fourth quarter and full year 2016 financial and operating results after the close of the U.S. financial markets on Tuesday, March 7, 2017. Management will host a conference call and live audio webcast to discuss these results and provi... More »
February 27, 2017
Lion Biotechnologies to Present at Upcoming Investor Conferences in March
SAN CARLOS, CA -- (Marketwired) -- 02/27/17 -- Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, announced today that company management will present a corporate update at two investor conferences in March: Cowen and Company 37th Annual Health Care Conference in Boston, MA on Monday, March 6, 2017 at 4:40 p.m. ET 29th Annua... More »